ArriVent BioPharma

ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations

NEWTOWN SQUARE, PA – ArriVent BioPharma, Inc. (Nasdaq: AVBP) presented final proof-of-concept results from its global Phase 1b FURTHER trial of firmonertinib, an oral targeted therapy for patients with non-small …

ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations Read More

Mineralys Therapeutics

Mineralys Reports Strong Phase 3 Results for Lorundrostat in High-Risk Hypertension Patients

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced new subgroup analyses from its Phase 3 Launch-HTN trial, showing that its investigational therapy lorundrostat significantly lowered blood pressure across multiple …

Mineralys Reports Strong Phase 3 Results for Lorundrostat in High-Risk Hypertension Patients Read More